DVAX axes CEO—halts I-O development—cuts workforce 37% (82 jobs): https://www.globenewswire.com/news-release/2019/05/23/1841968/0/en/Dynavax-Announces-Strategic-Restructuring-to-Focus-on-its-Vaccine-Business.html The stock is -7% in AH trading.